Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data

Kyowa Kirin will file for rocatinlimab’s US approval, which was once Amgen’s most late-stage pipeline candidate.

Sanofi's genetic disorder drug shows mixed results in late-stage trials

By Bhanvi Satija LONDON, Feb 2 (Reuters) - French drugmaker Sanofi said on Monday that its experimental genetic disorder ...
IFA Magazine

3 in 5 Brits now use AI for self-diagnosis in health

Brits are now using AI to self-diagnose. And 1 in 10 (11%) claim using AI to self-diagnose helped improve their condition.
Asianet Newsable on MSN

Regeneron stock slips premarket even after Wall Street lifts targets on strong Q4 — what’s weighing on the stock?

Analysts said near-term catalysts remain limited, with Phase 3 melanoma data as the next key event to watch.
InStyle on MSN

Martha Stewart, 84, my mom, 60, and I, 25, agree: These are the 6 best age-reversing beauty secrets from $8

Including picks from Mario Badescu and Maybelline.